a digital currency, Block

21st century business herald reporter learned exclusively from insiders that this week, the personal pension expansion policy will be announced, "the time may be December 12th". It is reported that the investable products included in personal pension may include over-the-counter products tracking nearly 20 broad-based indexes such as Shanghai and Shenzhen 300 Index, CSI 500 Index, CSI 800 Index, GEM Index and Kechuang 50 Index.At present, there is nothing wrong with the medium and long-term trend, so don't worry too much. Strategically, we will continue to watch more. Tactically, we will follow the trend and take the initiative step by step.There will be no surprises on Thursday!

There will be no surprises on Thursday!A shares: the latest release of Shanghai Stock Exchange! Incremental funds are coming, and it is likely to continue to rise on Thursday!This afternoon, the Government of the Hong Kong Special Administrative Region welcomed the passage of the Stamp Duty Legislation (Miscellaneous Amendments) Bill 2024 by the Legislative Council, which exempted the transfer of shares or units of real estate investment trusts and the securities distribution business of option makers, and revised the stamp duty collection arrangements under the paperless securities market system in Hong Kong.

If we can continue to cut interest rates in December, it will undoubtedly be a big plus for A shares, and the pressure on the exchange rate will be further reduced, which may become a turning point in the short term.Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.